Bionexus Gene Lab Corp. — Form 10-Q Summary
Business Context and Reporting Period
BioNexus Gene Lab Corp. filed an unaudited Form 10-Q for the three months ended March 31, 2023. The company operates primarily through Malaysian subsidiaries in two businesses: BioNexus Malaysia, which provides molecular and RNA-based disease screening services, and Chemrex, a wholesale industrial chemicals distributor. Chemrex generated 99.7% of consolidated revenue during the quarter.
Key Financial Metrics
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | $2.377 million | $3.029 million | Down 21.5% |
| Gross profit | $368,897 | $356,333 | Up 3.5% |
| Gross margin | 15.5% | 11.8% | Up approximately 3.7 percentage points |
| Operating income/(loss) | $(50,631) | $34,691 | Declined to a loss |
| Net income/(loss) | $(69,066) | $17,066 | Declined to a loss |
| Net margin | (2.9%) | 0.6% | Down approximately 3.5 percentage points |
| Comprehensive loss | $(108,105) | $(51,710) | Loss increased |
| Cash flow from operations | $(118,297) | $(37,839) | Use of cash increased |
| Cash flow from investing | $(5,056) | $(197,133) | Lower investment outflows |
Cash and cash equivalents were $1.973 million at March 31, 2023, consisting of $406,787 in cash and $1.566 million in fixed deposits. Working capital was $3.895 million, compared with $4.018 million at December 31, 2022. Total assets were $8.187 million and total liabilities were $1.630 million. The company disclosed operating lease liabilities of $52,409, including $16,733 due within one year; no traditional borrowings or senior debt were disclosed.
Trade receivables were $2.529 million and inventories were $900,000. Management stated that all trade receivables were collectible and recorded no allowance for impairment. Stockholders’ equity was $6.557 million, and 173,718,152 common shares were outstanding at March 31, 2023.
Material Changes Versus the Prior Comparable Period
- Revenue fell $651,740, principally because Chemrex reduced selling prices after lower Malaysian material costs and adjusted its customer and logistics strategy.
- Chemrex revenue declined 21.1% to $2.370 million, while its gross profit increased 7.9% to $366,808 because cost of revenue declined faster than sales.
- BioNexus Malaysia revenue declined 69.4% to $7,436 as post-COVID concerns reduced visits to diagnostic centers and demand for RNA screening.
- Consolidated gross profit increased despite lower revenue, producing a 15.5% gross margin versus 11.8% in the prior-year quarter.
- General and administrative expenses increased 45.9% to $536,872. Holding-company expenses rose approximately 310%, primarily due to SEC and S-1 filing fees, advisory and consultant fees, independent director and audit committee fees, compliance services, and shareholder maintenance costs.
- Other income increased to $117,344 from $46,394, driven primarily by fair-value gains on investments, bank interest, and unrealized foreign exchange gains.
- The company recorded a $39,039 foreign-currency translation loss in other comprehensive income, compared with a $68,776 loss in Q1 2022.
- Cash used in operations increased to $118,297, while investing cash use declined substantially because the company made fewer investments and capital expenditures.
Guidance, Outlook, Risks, and Unusual Items
Management stated that cash flow from operations, together with existing resources, is expected to support the current level of operations for at least the next 12 months. The filing does not provide formal revenue or earnings guidance.
Management described a proposed $28 million nationwide RNA screening project for Malaysia. The federal government was studying the proposal as of the filing, and Sabah’s state government reportedly planned to allocate $2.5 million for a laboratory in Kota Kinabalu. The company also stated that it had been advised to submit an application for a $2 million technology grant. These initiatives were proposed or under consideration and were not presented as committed funding or contracted revenue.
Key risks include weak demand for RNA screening following the COVID-19 pandemic, continued pressure on Chemrex customers and manufacturers from supply-chain disruption and lower demand, competition and pricing pressure, reliance on Malaysian operations, foreign-exchange volatility, regulatory requirements, the need for additional financing or resources as the business expands, and limited trading-market depth and potential sales of large blocks of securities.
The company reported that disclosure controls were effective as of March 31, 2023. Management also stated that material weaknesses in internal control over financial reporting had improved but that further improvement was required, including better segregation of duties. The company remains reliant on outside professionals and consultants while remedial actions are implemented. No material legal proceedings, defaults, or unregistered equity sales were reported.
Important Facts for Investors to Verify
- Whether the proposed federal RNA screening project, Sabah laboratory funding, or technology grant progresses to binding agreements or actual cash receipts.
- Whether Chemrex can sustain improved gross margins while revenue and selling prices remain under pressure.
- Whether BioNexus Malaysia can restore meaningful screening revenue after the substantial year-over-year decline.
- The sustainability of operations given the quarterly operating cash outflow and the company’s reliance on operating revenues.
- The status and remediation of the reported internal-control material weaknesses.
- The collectibility and aging of the $2.529 million trade receivables, particularly because no allowance was recorded.
- The impact of foreign-exchange movements on reported assets, equity, and comprehensive income.
- The effect of holding-company, compliance, financing, and potential capital-raising costs on future profitability and share dilution.